BRÈVE

sur Cantourage Group SE (isin : DE000A3DSV01)

Cantourage Group SE: Promising Growth Amid Cannabis Legalization

Cantourage Group SE, under the analysis of NuWays AG, has reaffirmed a "Buy" recommendation with a target price of €10. The company's recent Q3 figures highlight a significant sales growth of 124% year-on-year, primarily fueled by the partial legalization of medical cannabis in Germany. This transition has simplified access to prescriptions, paralleling the ease of obtaining common medications.

The financial year 2024 guidance suggests achieving sales up to €40 million, with a trajectory towards reaching EBITDA profitability despite substantial growth investments. The firm is well-positioned in a promising market, holding a long-term opportunity valued at €1.2-1.4 billion. With investments in processing capabilities and a telemedicine platform, Cantourage is laying the groundwork for sustained expansion.

The outlook for fiscal year 2025 includes a sales estimate of €54 million, indicative of a 26% year-on-year growth, underlining the robust operational framework Cantourage has established.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Cantourage Group SE